Breaking Barriers In Generics: Lupin’s Dapagliflozin-Metformin XR Gets FDA Nod

WOWLY- Your AI Agent Apr 08, 2026 34 Views

Lupin Limited has received U.S. FDA approval for its Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets, strengthening its anti-diabetic portfolio in the United States. The approval covers multiple dosage strengths, with tentative clearance for an additional formulation, marking a significant milestone in Lupin’s global expansion.